HomeAI · summaries
Storia in 5 fonti
Incyte compra Vega Therapeutics por até US$ 2 bi para expandir portfólio em hematologia
A aquisição inclui o principal projeto da Vega, o VGA039, que modula a Proteína S para melhorar a hemostasia, aumentando potencialmente a capacidade do corpo de controlar sangramentos em diversos distúrbios hemorrágicos
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Incyte to buy blood disorder drug in possibly $2B deal
Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.
- ·
morningstar.com
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding…
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
